% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Neumaier:889078,
      author       = {Neumaier, Felix and Zlatopolskiy, Boris D. and Neumaier,
                      Bernd},
      title        = {{N}uclear {M}edicine in {T}imes of {COVID}-19: {H}ow
                      {R}adiopharmaceuticals {C}ould {H}elp to {F}ight the
                      {C}urrent and {F}uture {P}andemics},
      journal      = {Pharmaceutics},
      volume       = {12},
      number       = {12},
      issn         = {1999-4923},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {FZJ-2021-00014},
      pages        = {1247},
      year         = {2020},
      abstract     = {The emergence and global spread of COVID-19, an infectious
                      disease caused by the novel coronavirus SARS-CoV-2, has
                      resulted in a continuing pandemic threat to global health.
                      Nuclear medicine techniques can be used for functional
                      imaging of (patho)physiological processes at the cellular or
                      molecular level and for treatment approaches based on
                      targeted delivery of therapeutic radionuclides. Ongoing
                      development of radiolabeling methods has significantly
                      improved the accessibility of radiopharmaceuticals for in
                      vivo molecular imaging or targeted radionuclide therapy, but
                      their use for biosafety threats such as SARS-CoV-2 is
                      restricted by the contagious nature of these agents. Here,
                      we highlight several potential uses of nuclear medicine in
                      the context of SARS-CoV-2 and COVID-19, many of which could
                      also be performed in laboratories without dedicated
                      containment measures. In addition, we provide a broad
                      overview of experimental or repurposed SARS-CoV-2-targeting
                      drugs and describe how radiolabeled analogs of these
                      compounds could facilitate antiviral drug development and
                      translation to the clinic, reduce the incidence of
                      late-stage failures and possibly provide the basis for
                      radionuclide-based treatment strategies. Based on the
                      continuing threat by emerging coronaviruses and other
                      pathogens, it is anticipated that these applications of
                      nuclear medicine will become a more important part of future
                      antiviral drug development and treatment.},
      cin          = {INM-5},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-5-20090406},
      pnm          = {573 - Neuroimaging (POF3-573)},
      pid          = {G:(DE-HGF)POF3-573},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {33371500},
      UT           = {WOS:000602408600001},
      doi          = {10.3390/pharmaceutics12121247},
      url          = {https://juser.fz-juelich.de/record/889078},
}